Antileukemic activity of sulforaphane in primary blasts from patients affected by myelo- and lympho-proliferative disorders and in hypoxic conditions by Fimognari, C et al.
Antileukemic Activity of Sulforaphane in Primary Blasts
from Patients Affected by Myelo- and Lympho-
Proliferative Disorders and in Hypoxic Conditions
Carmela Fimognari1*, Eleonora Turrini1, Piero Sestili2, Cinzia Calcabrini2, Giovanni Carulli3,
Giulia Fontanelli3, Martina Rousseau3, Giorgio Cantelli-Forti1, Patrizia Hrelia4
1Department for Life Quality Studies, Alma Mater Studiorum-University of Bologna, Rimini, Italy, 2Department of Biomolecular Sciences, University of Urbino "Carlo Bo",
Urbino, Italy, 3Division of Hematology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 4Department of Pharmacy and BioTechnology,
Alma Mater Studiorum-University of Bologna, Bologna, Italy
Abstract
Sulforaphane is a dietary isothiocyanate found in cruciferous vegetables showing antileukemic activity. With the purpose of
extending the potential clinical impact of sulforaphane in the oncological field, we investigated the antileukemic effect of
sulforaphane on blasts from patients affected by different types of leukemia and, taking into account the intrinsically
hypoxic nature of bone marrow, on a leukemia cell line (REH) maintained in hypoxic conditions. In particular, we tested
sulforaphane on patients with chronic lymphocytic leukemia, acute myeloid leukemia, T-cell acute lymphoblastic leukemia,
B-cell acute lymphoblastic leukemia, and blastic NK cell leukemia. Sulforaphane caused a dose-dependent induction of
apoptosis in blasts from patients diagnosed with acute lymphoblastic or myeloid leukemia. Moreover, it was able to cause
apoptosis and to inhibit proliferation in hypoxic conditions on REH cells. As to its cytotoxic mechanism, we found that
sulforaphane creates an oxidative cellular environment that induces DNA damage and Bax and p53 gene activation, which
in turn helps trigger apoptosis. On the whole, our results raise hopes that sulforaphane might set the stage for a novel
therapeutic principle complementing our growing armature against malignancies and advocate the exploration of
sulforaphane in a broader population of leukemic patients.
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Introduction
Sulforaphane (SR) is a dietary isothiocyanate found in
cruciferous vegetables able to provide protection against multistep
carcinogenesis [1]. Epidemiological studies evidenced an inverse
correlation between the consumption of a diet rich in cruciferous
vegetables (i.e., broccoli and cabbage) and the incidence of breast,
lung, prostate, colon, and bladder cancer [2–7], largely attributed
to the activity of isothiocyanates derived from the metabolism of
glucosinolates that accumulate in cruciferous vegetables [8]. SR is
a highly reactive and hydrophobic compound that can alter many
cellular processes. Inhibition of cell proliferation, increased
apoptosis, anti-inflammatory and antioxidant activities, induction
of phase-II detoxification enzymes, inhibition of cyclooxygenase 2,
and various other mechanisms have been proposed to explain the
anticancer effects of SR [9].
SR induces apoptosis in several cancer cell lines, such as T-cell
leukemia, breast, colon, and prostate cancer, by targeting different
molecules, such as caspases, PARP, p21, p53 and Bax [10–14]. SR
also blocks cell cycle through the modulation of G1/S and G2/M
phases and alters the levels of cyclin A, cyclin B1, cyclin D1,
p21cip1/waf1, and KLF4 [12,15–19]. The antileukemic effect of
SR was demonstrated in many different cell lines and, recently,
also in blasts from pediatric patients with acute lymphoblastic
leukemia (ALL) [20].
Leukemias are malignant neoplasms involving cells originally
derived from hematopoietic precursor cells that include many
diverse and biologically distinct subgroups. All leukemias start in the
bone marrow, that is diffusely replaced by abnormally proliferating
neoplastic cells. The neoplastic cells may spill out of the bone
marrow and reach the blood, where they may be present in large
numbers, resulting in the clinical presentations of the disease.
Generally, the leukaemias can be divided into acute myeloid
leukemia (AML) and related disorders, B-lymphoblastic leukemias,
T-lymphoblastic leukemias, leukemias of ambiguous lineage [21].
Although leukemia is the most common malignancy among
children and adolescents, the majority of cases of leukemia occur
in older people [22].
The treatment of leukemia still largely revolves around
chemotherapy to induce a complete remission and to consolidate
this with further cycles of chemotherapy. For example, the
standard therapy of AML is based on the association of an
anthracycline and ARA-C and the efficacy of such therapy still is
unsatisfactory, since the rate of complete remission ranges 30–
60%, depending on age, and the survival rate has not changed
significantly in years [23].
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Several new therapeutic approaches are under investigation,
alone or in combination with conventional chemotherapy. Despite
the development of multiple new agents, the development of
chemoresistance frequently hampers the successful treatment of
acute and chronic leukemias either at the initial presentation or
(more frequently) following primary or subsequent relapses [24],
and relapse continues to be the most common cause of death [25].
Those therapeutic issues can also be imputable to tumor
microenvironment, which is characterized not only by marked
gradients in drug concentration, but also by regions of hypoxia,
which can influence tumor cell sensitivity to drug treatment.
Taking into account the intrinsically hypoxic nature of bone
marrow, hypoxia is also an important environmental factor in
leukemia [26].
Thus, leukemias remain a formidable therapeutic challenge that
requires the identification and the development of novel agents for
the treatment of this disease.
Based on these considerations and with the aim to extend the
potential clinical impact of SR in the oncological field, we
investigated whether purified SR is effective against hematological
malignancies. To this end, we explored the antileukemic effect of
SR on blasts from patients affected by different types of leukemia.
In particular, we tested SR on patients with chronic lymphocytic
leukemia (CLL), AML, T-cell ALL (T-ALL), B-cell ALL (B-ALL),
and blastic NK cell leukemia (BNKAL). Since SR activity was
marked on samples from acute leukemias, we next analyzed the
proapoptotic activity of SR in two acute leukemia cell lines. To
better understand whether the level of oxygen is relevant for the
therapeutic efficacy of SR, we treated a leukemia cell line with SR
in hypoxic conditions and analyzed the formation of ROS and the
induction of apoptosis.
Materials and Methods
Chemicals
Ethidium bromide, NaOH, 29,79-dichlorofluorescein-diacetate
(DCFH-DA), chloroform, phenol, NaH2PO4 were purchased from
Sigma (USA). Synthetic DL- SR was dissolved in dimethyl
sulfoxide (DMSO) to generate a 40 mM stock concentration and
stored at 220uC. Cells were treated with different concentrations
of SR (0.0–30.0 mM), selected on the basis of previous studies
performed on leukemia cells [15].
Leukemic cell lines
REH (acute lymphocytic leukemia) and HL-60 (acute promy-
elocytic leukemia) cell lines were bought from ATCC-LGC, grown
in suspension and propagated in RPMI 1640 supplemented with
10% (REH) or 20% (HL-60) heat-inactivated bovine serum, 1%
antibiotics (all obtained from Sigma). To maintain exponential
growth, the cultures were divided every third day by dilution to a
concentration of 16105 cells/mL. Cells were treated with different
concentrations of SR for different times at 37uC in both normoxic
(20% O2) and hypoxic conditions.
Hypoxic conditions
Leukemic cells were cultivated in an INVIVO2 200 hypoxia
workstation (Ruskinn Technology LTD, England) at ,1% O2.
Treatments and all cell manipulations were performed in the
workstation, thus ensuring a full maintenance of hypoxia for the
entire duration of the experiments.
Ethics statement
The described study was approved (Comitato Etico e Sper-
imentazione del Farmaco dell’Azienda Ospedaliero-Universitaria
Pisana) and written informed consent was obtained from the
patients. All clinical investigation was conducted according to the
principles expressed in the Declaration of Helsinki.
Hematologic patients
Patients include cases of CLL (n= 2), AML (n= 8), B-cell ALL
(n= 1), T-cell ALL (n = 2), BNKAL (n= 1). The general charac-
teristics of patients are shown in Table 1. Diagnosis of leukemia
was established according to the 2008 WHO classification [21]
and by the combination of morphological, immunological,
cytogenetic and molecular methods, which were applied to
peripheral blood samples. The immunological assays were made
by fluorochrome-conjugated monoclonal antibodies and analysis
Table 1. Clinical features of patients.
Patients Age Sex Diagnosis Timing Previous therapy
1 67 F CLL Stable disease None
2 76 F CLL Stable disease None
3 38 M AML Studied at diagnosis None
4 39 M AML Non-responder 3+7a
5 31 F AML Non-responder 3+7
6 19 F AML Studied at diagnosis None
7 30 F AML Studied at diagnosis None
8 60 F AML Relapse 3+7, allogeneic HSCTb
9 47 F AML Studied at diagnosis None
10 24 M T-ALL Studied at diagnosis None
11 24 F T-ALL Studied at diagnosis None
12 48 M B-ALL Studied at diagnosis None
13 55 F AML Studied at diagnosis None
14 31 F BNKAL Studied at diagnosis None
aa combination drug protocol used as induction chemotherapy and consisting of three days of anthracyclines and seven days of cytarabine;
ballogeneic HSCT: transplantation of allogeneic hematopoietic stem cells.
doi:10.1371/journal.pone.0101991.t001
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by a three-laser (488, 633, 405 nm)-equipped flow cytometer
(FacsCanto II, Becton Dickinson, USA). A six-color method was
applied; therefore the following fluorochrome combination was
used: fluorescein isothiocyanate, phycoerythrin, peridinin chloro-
phyll protein complex, phycoerythrin-cyanine 7, allophycocyanin,
allophycocyanin-cyanine 7. Diagnosis of acute leukemia was
established by means of a wide panel of monoclonal antibodies,
which included: CD45, CD13, CD33, CD34, CD117, HLA-DR,
CD4, CD14, CD64, CD38, MPO, CD11b, CD16, CD15, CD56,
CD7, CD19, CD3, CD2, CD5, CD4, CD8, CD10, CD20, CD58,
TdT (from Becton Dickinson) and rabbit polyclonal F(ab9)2
antibodies directed to cyIgM and surface immunoglobulin K and
lambda chains (from Dako, USA). CLL samples were subjected to
an antibody panel which included CD45, CD3, CD4, CD8,
CD16-56, CD5, CD19, CD20, CD23, CD22, CD79b, CD200,
CD38, CD25, CD11c, surface immunoglobulin K and lambda
chains. Patients were studied at the time of diagnosis; one patient
was studied during his first relapse and two patients in a phase of
resistant disease.
Preparation of leukemic cells
Peripheral blood samples of patients were collected in tubes
containing preservative-free heparin. Leukemic cells were ob-
tained by Ficoll-Histopaque density gradient centrifugation. 3 mL
of Histopaque 1.077 g mL21 were placed into a 10 mL plastic
centrifuge tube, overlaid with 3 mL anticoagulated blood diluted
1:1 with phosphate-buffered saline (PBS), and centrifuged at
4006g for 30 min at room temperature. Interphase mononuclear
cells banded at the interface between the plasma and the
Histopaque were recovered, washed twice with PBS and then
resuspended in RPMI 1640 medium (Sigma) containing 15%
heat-inactivated bovine serum. The samples always contained .
95% blasts.
Flow cytometry
All flow cytometric analyses were performed by using the
easyCyte 5HT flow cytometer (Millipore Guava Technologies,
USA).
Detection of apoptosis
After 24, 48 or 72 h of treatment with different concentrations
of SR, aliquots of 2.06104 cells were stained with 100 mL of
Guava Nexin Reagent containing ANNEXIN-V-phycoerythrin
and 7-amino-actinomycin D. During apoptosis, the cells react to
annexin V once chromatin condenses but before the plasma
membrane loses its ability to exclude 7-amino-actinomycin D.
Hence, by staining cells with a combination of phycoerythrin
annexin V and 7-amino-actinomycin D it is possible to detect non
apoptotic live cells, early apoptotic cells and late apoptotic or
necrotic cells. Cells were incubated for 20 min at room
temperature in the dark and then analyzed by flow cytometry.
Fast halo assay (FHA)
The assay has been carried out as previously described [27,28].
Briefly, after the treatments, the cells were resuspended at
4.06104/mL in ice-cold PBS containing 5 mM EDTA: 25 mL of
this cell suspension was diluted with an equal volume of 2% low
melting agarose in PBS and immediately sandwiched between an
agarose-coated slide and a coverslip. After complete gelling on ice,
the coverslips were removed and the slides were immersed in
NaOH 300 mM for 15 min at room temperature. Ethidium
bromide (10 mg/mL) was directly added to NaOH during the last
5 min of incubation. The slides were then washed and destained
for 5 min in distilled water. The ethidium bromide-labelled DNA
was visualized using a Leica DMLB/DFC300F fluorescence
microscope (Leica Microsystems, Germany) equipped with an
Olympus Colorview IIIU CCD camera (Olympus Italia Srl, Italy)
and the resulting images were digitally recorded on a PC and
processed with an image analysis software (Scion Image, Scion
Corporation, USA). The amount of fragmented DNA diffusing out
of the nuclear cage, i.e. the extent of strand scission, was quantified
by calculating the nuclear diffusion factor (NSF), which represents
the ratio between the total area of the halo and nucleus and that of
the nucleus. To allow the detection and recognition of DNA
double strand breaks (DSBs) FHA was carried out at non-
denaturing pH conditions as follows: the slides were submersed in
a lysis solution (0.15 M NaOH, 0.1 M NaH2PO4, 1 mM EDTA,
Figure 1. Fraction of apoptotic cells induced by SR on mononuclear cells isolated from CLL patients. Cells were treated with 0 to 30 mM
SR for 24 or 48 h.
doi:10.1371/journal.pone.0101991.g001
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Figure 2. Fraction of apoptotic cells induced by SR onmononuclear cells isolated from AML patients. Cells were treated with 0 to 30 mM
SR for 6, 24, 48 or 72 h.
doi:10.1371/journal.pone.0101991.g002
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Triton6100 1% v/v, pH 10.1) for 10 min, incubated for further
15 min in PBS (pH 7.4) containing 0.1 mg/mL RNase (bovine
pancreas Type 1A); ethidium bromide was directly added to this
solution during the last 5 min of incubation. The slides were then
washed and destained for 5 min in distilled water and analyzed as
described above.
ROS detection
DCFH-DA was used for ROS detection. DCFH-DA is cleaved
intracellularly by nonspecific esterases to form 29,79-dichlorodihy-
drofluorescein (DCFH), which is further oxidized by ROS to form
the highly fluorescent compound 29,79-dichlorodihydrofluorescein
(DCF). Briefly, 16106 cells were pre-treated with 15 or 30 mM SR
for 30, 60, 180 or 360 min. Then, samples were washed and
16106 cells were stained with 10 mM DCHF-DA. After 20 min of
incubation at 37uC, fluorescence intensity was monitored by flow
cytometry. Data were expressed as percentage of the control
(untreated cells).
Analysis of apoptotic proteins
After treatment with SR, 16106 cells were fixed and
permeabilized by 2% of paraformaldehyde in PBS 16 and 90%
of cold methanol. They were then incubated with Bax (1:100,
Santa Cruz Biotechnology, Santa Cruz, CA, USA), Bcl-2 (1:100,
Santa Cruz Biotechnology), p53 (1:100, Invitrogen), or isotype-
matched negative control (1:100, e-Bioscience, San Diego, CA,
USA) antibodies. The cells were washed and incubated with
fluorescein isothiocyanate-labeled secondary antibody (1:100,
Sigma). The cells were then analyzed to quantify fluorescein
isothiocyanate binding by flow cytometry. Mean fluorescence
intensity values were calculated. Non-specific binding was
excluded by gating around those cells which were labeled by the
fluorescein isothiocyanate-conjugate isotype control.
Analysis of cell cycle
Cell were treated with different concentrations of SR for 8, 24
and 48 h, and then fixed with ice-cold ethanol. Samples were then
Figure 3. Fraction of apoptotic cells induced by SR on mononuclear cells isolated from ALL and BNKAL patients. Cells were treated
with 0 to 30 mM SR for 6, 24 or 48 h.
doi:10.1371/journal.pone.0101991.g003
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stained with 200 mL of Guava Cell Cycle Reagent, containing
propidium iodide that allows evaluating cellular DNA content.
During the S phase of cell cycle, cells duplicate their content of
DNA that will be double in the G2/M phase compared to the G0/
G1 phase. Cells were incubated at room temperature for 30 min in
the dark, and analyzed via flow cytometry.
mRNA expression
After 6, 24 or 48 h of treatment in normoxic or in hypoxic
conditions, total RNA was isolated using miRVanaTM miRNA
Isolation kit (Life Technologies, CA, USA), according to
manufacturer’s instructions. Briefly, cells were treated with lysis
buffer, then subjected to acid - phenol: chloroform extraction.
Ethanol was added to samples and they were passed through a
filter cartridge containing a glass-fiber filter which immobilizes the
RNA. The filter was washed and RNA was eluted with a low ionic
strength solution. Total collected RNA was used for reversed
transcription by High Capacity cDNA Reverse Transcription kit
(Life Technologies). Briefly, 200 ng total RNA were added to
10 mL reaction kit mixture with RNase inhibitor according to
manufacturer’s instructions as well as the thermal cycler condi-
tions. The obtained cDNA was stored at220uC. Quantification of
Bax, Bcl-2, TP53 and 18 S, as endogenous control, was performed
in triplicate by real-time PCR (ABI Prism 7900HT, Life
Technologies), using Universal Master Mix and TaqMan assays
Hs00180269_m1 (Bax), Hs00608023_m1 (Bcl-2),
Hs01034249_m1 (p53) and Hs99999901_s1 (18S) (Life Technol-
ogies). Each measurement was conducted in triplicate.
Statistical analysis
All results are expressed as the mean 6 SEM of at least four
different experiments. Differences in mRNA expression are
reported as value 6 SEM and represent the relative expression
calculated through the 2-DDCt method [29]. One way ANOVA,
followed by Dunnett or Bonferroni as post test was used to
evaluate differences between treatments. GraphPad InStat version
5.0 (GraphPad Prism, San Diego, CA, USA) was used for all
statistical analyses. P,0.05 was considered significant.
Results
Firstly, we examined the effects of different concentrations of
SR on primary blasts collected from leukemic patients. Three
samples (patients n. 6, 7 and 8) were excluded because they had a
% of viable cells lower than 10% when untreated. SR seems not to
have any activity on samples from patients with CLL. Even high
concentrations (30 mM) and long times (48 h) of treatment only
slightly increased the % of apoptotic cells compared to the control
(42.3% vs. 32.4%, sample n. 1) (Fig. 1).
The pro-apoptotic effect of SR was recorded, however, in
samples from patients with AML, where the % of apoptotic cells
induced following treatment reached 49% (sample n. 5) (Fig. 2).
Both samples 3 (about 45% apoptosis increase vs. control at
30 mM after 48 h incubation) and 5 (about 40% apoptosis increase
vs. control at 30 mM after 48 h incubation) were highly sensitive to
SR treatment (Fig. 2). In contrast, samples 4 (about 28% apoptosis
increase vs. control at 30 mM after 48 h incubation), 13 (about
28% apoptosis increase vs. control at 30 mM after 24 h
incubation), and 9 (about 13% apoptosis increase vs. control at
15 and 30 mM after 24 h incubation) were less sensitive (Fig. 2). Of
note, the effect of SR was marked also on samples from non-
responder patients. In the sample n. 5, for example, the fraction of
apoptotic cells recorded after 48 h of treatment with 30 mM SR is
more than 5 times higher than that recorded in untreated cultures
(Fig. 2).
The activity of the isothiocyanate on samples from patients with
ALL did not differ between T- or B- cell leukemia. The most
marked effect was definitely observed on the sample from patient
suffering from T-ALL, where the % of apoptotic cells reached
55% (vs. 27% in the control cultures) (sample n. 10) (Fig. 3). The
effect on the other sample of T-ALL was milder (sample n. 11)
(about 20% apoptosis increase vs. control at 15 mM after 48 h
incubation) (Fig. 3). A 28% increase in the apoptotic effect was
reached in the B-ALL sample at 15 mM after 24 h incubation
(sample n. 12) (Fig. 3).
SR has not been shown to have any activity on the sample from
BNKAL (sample n. 14) (Fig. 3).
Figure 4. Induction of apoptosis by SR in normoxic and hypoxic conditions on REH cells. Cells were treated with 0 to 30 mM SR for 24 h.
The % of apoptotic cells recorded in the untreated cultures was subtracted from that observed in cultures treated with SR. Data are presented as
mean 6 SEM of at least four different experiments.
doi:10.1371/journal.pone.0101991.g004
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Figure 5. SR induces DNA damage in REH cells. Cells were treated with increasing concentrations of, or for increasing time intervals with, SR
and immediately assayed for DNA breakage with FHA. A) DNA single strand breakage induced by 3 h SR treatment in REH cells. B) DNA single strand
breakage induced by 30 mM SR in REH cells as a function of incubation time. Data are presented as mean 6 SEM of three different experiments. C)
and D) Representative, digitally pseudocolored (ICA look up table of the Image J software) micrographs of FHA-processed control (C) or 30 mM SR-
treated (D) REH cells are also shown: note the wide halos in D as compared to C. Also shown (panel A, inset) the extent of DNA double strand
breakage caused by SR (30 mM for 3 h) or etoposide (1 mg/mL for 3 h) in REH cells. Data are expressed as NSF (nuclear diffusion factor), which
represents the ratio between the total area of the halo and nucleus and that of the nucleus.
doi:10.1371/journal.pone.0101991.g005
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We next analyzed the proapoptotic activity of SR and initially
determined the induction of apoptosis after treating two acute
leukemia cell lines with different doses of SR for 24 h. In REH
cells, we observed a clear increase in the fraction of apoptotic cells
under all conditions (Fig. 4). Similar results were observed in HL-
60 cells, where we recorded a two-fold increase with respect to
controls after 48 h of treatment.
Genomic DNA breaks represent an important trigger of
apoptosis. Thus, we investigated the effect of SR on REH cells.
REH cells were exposed to SR (10, 20 and 30 mM) for 3 h, and
analyzed immediately for direct DNA strand scission using the
Figure 6. Effect of SR on ROS levels determined in normoxic (A) and hypoxic (B) conditions on REH cells. Cells were treated for 30–
360 min with SR to analyze the oxidation state of the cell by using DCFH-DA as fluorogenic probe. Results are expressed as DCF (29,79-
dichlorodihydrofluorescein) fluorescence (% of control) and are means 6 SEM of four independent experiments.
doi:10.1371/journal.pone.0101991.g006
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Figure 7. Effect of SR on p53, Bax and Bcl-2 protein expression determined in normoxic and hypoxic conditions on REH cells. Cells
were treated with 0 to 30 mM SR for 24 h. Data are presented as mean 6 SEM of at least four different experiments.
doi:10.1371/journal.pone.0101991.g007
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sensitive FHA. With this technique, DNA fragments resulting from
the cleavage of DNA itself diffuse out of the nuclear cage as an
inverse function of their size, thus producing a concentric halo
whose radius reflects the extent of DNA damage. Halo formation
was monitored at the single cell level with fluorescence micros-
copy, as seen in the representative micrographs shown in Fig. 5C–
D. The results obtained indicate that SR promotes the formation
of DNA breaks in a dose-dependent fashion (Fig. 5A). Formation
of DNA breaks as a function of treatment time with 30 mM SR is
linear over time (Fig. 5B).
We then explored the nature of SR-induced DNA lesions by
analyzing the nuclear DNA of treated cells at lower -non
denaturing conditions- lysis pH values, i.e. 9.3. Indeed, while
operating at pH 13.00 does not allow to distinguish DNA single
strand breaks (SSBs) from DSBs, at pH 9.3 nuclear DNA is not
hydrolyzed into the two chains and only the DNA fragments
resulting from double strand cleavage can be detected. Under
these latter conditions (i.e. pH 9.3), no difference in terms of DNA
fragmentation could be observed between treated (30 mM SFN for
3 h) and untreated REH cells (Fig. 5A, inset), thus suggesting that
the lesions caused by SFN observed at pH 13.00 are frank SSBs.
On the contrary, treatment of REH cells with etoposide (1 mg/ml
for 3 h), included as a representative inducer of DNA DSBs,
resulted in extensive DNA double strand breakage (Fig. 5A, inset).
As to the mechanism responsible for the induction of DNA
damage in SR-treated cells, we previously reported that SR
promotes the mitochondrial formation of ROS [30], which are the
ultimate species mediating DNA cleavage. We then investigated
the formation of ROS in REH cells. After 3 h of treatment with
SR 30 mM, we recorded a significant induction of ROS. Results
depicted in Fig. 6 indicate that SR caused the conversion of
DCFH into its fluorescent by-product, a process which reflects the
formation of ROS. Treatment of cells with SR greatly increased
the formation of ROS. The effect was evident after just 30 min of
treatment.
Chelation of iron ions blocks the Fenton reaction and thus the
production and the propagation of oxygen radicals - i.e. the species
responsible for DNA and cellular damages - within the cells [31].
The presence of the iron chelator o-phenanthroline prevented the
formation of DNA breaks and reduced DCFH oxidation (data not
shown). Thus, as to nuclear DNA, the data described so far
indicate that REH, according to previous data obtained in Jurkat
cells [30], are prone to the DNA damaging action caused by SR,
and that ROS are the species mediating this effect in both cell
lines.
In the second part of our work, we treated REH cells with
different concentration of SR in hypoxic conditions and analyzed
the formation of ROS and the induction of apoptosis.
Fig. 6 shows the formation of ROS in normoxic and hypoxic
treatment protocols. ROS formation was also observed in hypoxic
conditions. The trend is similar in both conditions, although the
formation of ROS is higher in normoxia (Fig. 6A). Of note, DNA
damage was observed also in hypoxic conditions after treatment
with SR (data not shown).
The proapoptotic effect of SR in hypoxia was lower than that
observed in normoxia (Fig. 4). As an example, after treatment with
SR 7.5 mM, we observed a four-fold increase with respect to
controls in normoxia and a two-fold increase in hypoxia. At the
highest concentration tested, we recorded a six-fold and about a
three-fold increase with respect to controls in normoxia and
hypoxia, respectively. After longer time of treatment (i.e. 48 h) in
hypoxic conditions, SR mainly induced necrotic events. As an
example, at SR 30 mM we recorded 30% of necrotic cells (vs. 10%
in the control) and 20% of apoptotic cells (vs. 15% in the control).
Figure 8. Effect of SR on p53, Bax and Bcl-2 mRNA relative expression calculated through the 2-DDCt method and determined in
normoxic and hypoxic conditions on REH cells. Cells were treated with 0 to 30 mM SR for 6, 24 or 48 h. Data are presented as mean6 SEM of at
least four different experiments.
doi:10.1371/journal.pone.0101991.g008
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This trend was not observed in normoxic conditions, where at SR
30 mM the % of necrotic cells was 25% (vs. 8% in the control) and
44% of apoptotic cells (vs. 10% in the control).
Survival of cancer cells is influenced by the interactions between
pro- and anti-apoptotic proteins. We then analyzed the expression
at mRNA and protein levels of some genes involved in the
regulation of apoptosis. Following 48 h-treatment in normoxic
conditions, SR induced a significant up-regulation of p53 and Bax
protein expression (Fig. 7). However, the expression of the same
genes at mRNA level seems more complex. After treatment with
SR for 6, 24 or 48 h, we mainly observed an up-regulation of p53
expression (Fig. 8), while a down-regulation of Bax expression was
recorded after 6 and 24 h of treatment. After 48 h, SR up-
regulated Bax expression (Fig. 8). The expression of Bcl-2 was
down-regulated at both mRNA and protein expression level and
following 6, 24 or 48 h of exposure to SR (Figs. 7 and 8).
In hypoxic conditions, we observed a similar trend. However,
the effects on p53 and Bax mRNA expression and the ratio of
Bax/Bcl-2 proteins were less marked than in normoxia (Figs. 7 and
8).
The antileukemic effect of SR is strengthened by the inhibition
of cell proliferation (Fig. 9) in both normoxic and hypoxic
exposure to SR. In both conditions, the effect was recordable
starting from the lowest concentration tested. However, the
mechanism by which SR inhibits cell-cycle progression is different
in the two treatment protocols. In normoxia, a block in G2/M
phase was recorded, while an increase in G1 phase was observed in
hypoxia.
Discussion
The main goal of this study was to test the antileukemic
properties of SR in hematological cancers. We found that
synthesized SR caused a dose-dependent induction of apoptosis
in acute leukemia cell lines and primary lymphoblasts from
patients diagnosed with B-ALL, T-ALL, and AML.
Due to the possibility to easily obtain blast samples from
leukemic patients, SR was tested on an ex vivo leukemia model. Ex
vivo samples represent a quite good surrogate for determining the
cellular response of the patient to the treatment and predicting the
clinical outcome [32–34]. This can not be realized by using cell
lines, which markedly differ from blasts directly taken from
leukemic patients in terms of growth kinetics and pharmacological
determinants [35]. By the ex vivo model and in accordance with
previous data [20,30], we confirmed that SR controlled the
expansion of leukemic cells. However, our results show that SR
can not be defined generically an antileukemic, as apparently it
acts only on patients with particular types of leukemia. Indeed, we
did not record any activity of SR on samples from CLL patients.
CLL is generally described as a disease of failed apoptosis.
Apoptosis resistance may stem from a combination of microen-
vironmental survival signals as well as from intrinsic alterations in
the apoptotic machinery and deregulation of components of the
DNA-damage response and repair pathways within the CLL cell
[36]. Moreover, CD40 signaling has been recognized as a strong
antiapoptotic pathway mediating drug resistance in vitro. All CLL
cells express CD40, and in vitro resistance can be induced in 100%
of patients [37]. The strong dependence on cellular and cytokine
components of the microenvironment makes the ex vivo manipu-
lation of CLL cells complex and resulting in biased findings [38].
Taking into account the absence of a cellular model for different
types of CLL [39], further research might explore the effects of SR
on blasts from CLL patients through the partial re-creation in vitro
of the CLL microenvironment, including in particular leukemic
cell survival signals.
One of the greatest problems for anticancer chemotherapy is
chemoresistance, which is less frequent ab initio and has a major
clinical impact during relapse. SR was tested also on non-
responder patients. Although the number of patients was limited, it
is interesting to note that SR retains its activity on this type of
patients.
One of the more significant findings to emerge from this study is
that SR exerts proapoptotic and antiproliferative effects in hypoxic
conditions. Reduced oxygen tension affects cellular metabolism
and the microenvironment, including pH level. These and other
modulations caused by hypoxia can affect the response to
pharmacological treatment [40]. Therefore, with the aim of
gaining further mechanistic insight into the antileukemic activities
of SR as well as the effects of the local environment on the
outcome of treatment, we investigated the effects of SR in hypoxic
conditions, which better mimics the tumor microenvironment in
vivo. Our findings demonstrate that, despite hypoxic culture
conditions, the antileukemic activity of SR is relatively preserved.
We indeed recorded induction of apoptosis and production of
ROS after treatment of leukemia cells with SR in both normoxic
and hypoxic conditions. As to the mechanism through which SR
induces apoptosis, an important trigger is likely to reside in its
ability of damaging nuclear DNA. Indeed DNA damage is known
as an event causally linked to the apoptotic commitment of target
cells. The mechanism whereby DNA breaks are produced clearly
Figure 9. Cell-cycle distribution following 24 h culture in the
absence or presence of SR in normoxic (A) and hypoxic (B)
conditions on REH cells. Data are means 6 SEM of four independent
experiments.
doi:10.1371/journal.pone.0101991.g009
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involves the intracellular generation of ROS. Paradoxically,
exposure of cells to low oxygen (hypoxia) leads to an increase in
mitochondrial production of ROS, that are central upstream
regulators of many of the cellular responses to hypoxia. Low levels
of ROS are required for cellular processes such as proliferation
and differentiation, while additional amounts of ROS above a
certain threshold may cause cell-cycle arrest and/or apoptosis.
The equilibrium of ROS concentration will thus be reached at the
point where maximal signaling is permitted without causing
irreversible damage to cellular components. Indeed, irreversible
damage to cellular proteins, DNA, or lipids seems to be the case as
compounds that raise ROS levels can effectively kill a variety of
tumor cell lines [41]. Increasing ROS levels may indeed represent
a therapeutic strategy to increase killing of cancer cells.
Accordingly with those observations, in our experimental setting
SR creates an oxidative cellular environment that induces DNA
damage and Bax and p53 gene activation, which in turn helps
trigger apoptosis. Indeed, the % of apoptotic cells and the up-
regulation of p53 and Bax are particularly marked in normoxic
conditions, where the production of ROS is higher than in
hypoxia. However, the effect of SR on the mRNA expression of
p53 and Bax is different, particularly for Bax, for which a down-
regulation was observed after short times of treatment with SR.
The quantification of both of these expression levels is not an
exercise in redundancy. Indeed, analyses of mRNA and protein
levels are complementary and both are necessary for a complete
understanding of how the cell works. The different modulation of
a gene at mRNA and protein levels caused by a xenobiotic can be
due to different reasons, such as the poor definition of the
complicated and varied post-transcriptional mechanisms involved
in turning mRNA into protein, or the different half lives of
proteins [42]. The differential effect of SR at mRNA and protein
level seems not be imputable to an inhibition of proteasome.
Instead, SR appears to stimulate proteasome [43,44]. Alternately,
a further study could assess the modulation by SR of microRNAs
that moderate the p53 and Bax transcriptional program.
The results of this investigation show that SR is also able to
inhibit cell-cycle progression through a block in the G2/M phase
in normoxia and in the G1 phase in hypoxia. The G2/M block
induced by SR in normoxia was reported in many cell lines [1].
The differential effect in hypoxic conditions is not surprising. As a
matter of fact, cells subject to severe hypoxia will arrest in G1 or
early S phase and cells in late S, G2 or M phase will finish cell
division and arrest in G1, unless the hypoxia is severe [45].
As to the concentrations of SR used in this study, they could be
not achievable from food supply. However, after a single oral dose
of SR at 150 mmol/kg in rat, plasma concentrations of SR
equivalents increase to 15.2 mM [46]. Furthermore, the potential
development of SR in clinical practice could lead to the
application of a drug delivery system to improve drug absorption.
In conclusion, in vitro and ex vivo experiments performed in the
present study suggest that SR could represent an interesting
therapeutic approach for patients affected by acute proliferative
disorders and might set the stage for a novel therapeutic principle
complementing our growing armature against malignancies. Large
clinical trials will be necessary to confirm this attractive perspective
in vivo.
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